20260803_OMED_Laporan Informasi dan Fakta Material_32116930_lamp3.pdf

                                      PRESS RELEASE

  OMED Reports 6M2026 Strong Growth, Net Profit Up 43.2% with
                Continued Margin Improvement
                                   Surabaya, July 31, 2026

PT Jayamas Medica Industri Tbk (“OMED” or the “Company”), an integrated medical device
manufacturer and distributor, delivered solid results in the first half of 2026 (6M2026),
recording strong sales and earnings growth accompanied by improved profitability.

OMED reported net sales of IDR1.167 trillion, an increase of IDR240.9 billion or 26.0% YoY
compared with IDR925.8 billion in 6M2025. The growth was supported by stronger demand
across several key product categories as well as the expansion of the Company’s distribution
and retail network.

In line with sales growth, operating profit rose to IDR231.5 billion, up IDR68.8 billion or 42.3%
YoY from IDR162.7 billion. The Company also recorded net profit of IDR221.5 billion, an
increase of IDR66.8 billion or 43.2% YoY from IDR154.7 billion. Basic earnings per share
(EPS) increased to IDR8.12 per share from IDR5.68 per share, representing approximately
43.0% YoY growth.

The Company’s profitability continued to improve compared with the same period last year,
with gross profit margin rising to 35.9% (from 33.8%), operating profit margin increasing to
19.8% (from 17.6%), and net profit margin improving to 19.0% (from 16.7%). Margin
improvement was driven by a higher contribution from higher-margin products, an improved
product mix, sales growth that outpaced the increase in operating expenses, foreign exchange
gains, and ongoing operational efficiency initiatives.

By product category, the highest growth came from Biotechnology and Laboratory, which grew
93.6% YoY, followed by Medical Consumables and Disposable Products (BMHP) at 30.2%
YoY, and Wound Care at 23.5% YoY. This performance reflects the Company’s success in
strengthening its higher value-added product portfolio.

The retail segment was the fastest-growing segment, with sales reaching IDR135.1 billion, up
35.4% YoY from IDR99.8 billion in 6M2025. The growth reflects the increasing contribution of
retail channels to the Company’s total revenue.

Entering the second half of 2026, OMED maintains a constructive outlook on the national
medical device industry despite ongoing global challenges such as geopolitical uncertainty,
energy price pressures, and foreign exchange volatility.

The Company reaffirmed that its 2026 targets and guidance remain on track, including
revenue of approximately IDR2.3 trillion or 10–15% YoY growth, gross profit margin in the low-
30% range, and export sales of USD1.0–1.5 million.